T1	intervention 32 48	N-Acetylcysteine
T2	condition 81 117	Anthracycline-Induced Cardiomyopathy
T3	No-of-participants 285 288	103
T4	eligibility 381 519	patients first diagnosed with breast cancer or lymphoma, who require chemotherapy, including anthracycline like adriamycine or epirubicine
T5	intervention-participants 566 568	50
T6	control 715 728	control group
T7	control-participants 732 734	53
T8	outcome-Measure 761 814	decrease in left ventricular ejection fraction (LVEF)
T9	outcome 963 978	primary outcome
T10	intervention-value 1042 1043	3
T11	intervention-participants 1044 1046	47
T12	intervention-value 1048 1052	6.4%
T13	control-value 1058 1059	1
T14	control-participants 1060 1062	52
T15	control-value 1064 1068	1.9%
T16	outcome 1085 1094	mean LVEF
T17	outcome 1262 1278	mean LVEF change
T18	outcome 1371 1415	Left ventricular (LV) end systolic dimension
T19	outcome 1529 1555	LV end diastolic dimension
T20	outcome 1621 1671	Peak E, A and E/A ratio change and cardiac enzymes
T21	outcome 1703 1733	Cumulative 12-month event rate
T22	intervention-value 1738 1740	6%
T23	control-value 1745 1749	3.8%
